Drugs / APL-130277
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02228590 | Aug → Nov 2014 | Parkinson disease | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03391882 | Dec 2018 → Aug 2021 | Parkinson disease | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02542696 | Aug 2015 → Nov 2022 | Parkinson disease | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APL-130277 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02542696 ↗ |